| Autor: |
Blanken, Annelies B., Raadsen, Reinder, Agca, Rabia, van Sijl, Alper M., Smulders, Yvo M., Nurmohamed, Michael T. |
| Předmět: |
|
| Zdroj: |
Rheumatology International; Feb2023, Vol. 43 Issue 2, p315-322, 8p |
| Abstrakt: |
Objective: To assess the effect of 4 years of anti-inflammatory therapy on markers of subclinical vascular disease in rheumatoid arthritis patients. Methods: Carotid intima media thickness (IMT), augmentation index (AIx@75) and pulse wave velocity (PWV) measurements were performed repeatedly in 61 RA patients (30 early RA starting with csDMARDs and 31 established RA starting with adalimumab) for 4 years. These markers were also measured in 29 controls with osteoarthritis at baseline (BL). Results: IMT and AIx@75 at BL were higher in RA compared to OA, while PWV was higher in OA. In RA patients, AIx@75 and PWV decreased in the first 6 months after starting anti-inflammatory therapy. At 48 M, the level of AIx@75 remained lower than before therapy, while PWV at 48 M was comparable to BL (AIx@75: BL 28% (95% confidence interval 25–30%), 6 M 23% (20–26%), 48 M 25% (22–28%); PWV: BL 8.5 (7.8–9.2), 6 M 8.0 (7.1–8.9), 48 M 8.6 (7.6–9.6) m/s). IMT remained stable. There was an effect of disease activity (longitudinally, adjusted for changes over time) on IMT, AIx@75 and PWV. Conclusion: This study suggests modest beneficial changes in some surrogate markers of subclinical vascular disease after anti-inflammatory therapy. These changes were associated with improvement in disease activity markers. Whether or not these beneficial changes ultimately predict a reduction in clinicalcardiovascular endpoints remains to be established in prospective studies. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink